Citations

Clear

410 citation(s) found for "Shu, Yu".

Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)
Kulke, Matthew H. , Ou, Fang-Shu, Niedzwiecki, Donna, Huebner, Lucas, Kunz, Pamela L. , Kennecke, Hagen F, Wolin, Edward M, Chan, Jennifer A, O’Reilly, Eileen M, Meyerhardt, Jeffrey A, Venook, Alan, Niedzwiecki, Donna , Meyerhardt, Jeffrey A. , Kunz, Pamela , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Kulke, Matthew H , Ou, Fang-Shu, Huebner, Lucas, Kennecke, Hagen F, Wolin, Edward M, Chan, Jennifer A, O’Reilly, Eileen M, Venook, Alan

Mayo Clinic

Endocrine-Related Cancer | March 25, 2022 | Volume: 29 | Issue: 6 | Pages: 335-344

10.1530/erc-21-0239 | PMID 35324465 Get It

Treatment with the MTOR inhibitor everolimus improves progression-free survival (PFS) in pancreatic neuroendocrine tumors (pNETs), but it is not known if the addition of a VEGF pathway inhibitor to an MTOR inhibitor enhances antitumor activity. We performed a randomized phase II study evaluating everolimus with or without bevacizumab in patients with advanced pNETs. One hundred and fifty patients were randomized to receive everolimus 10 mg daily with or without bevacizumab 10 mg/kg i.v. every 2 weeks. Patients also received standard dose of octreotide in both arms. The primary endpoint was PFS, based on local investigator review. Treatment with the combination of everolimus and bevacizumab resulted in improved progression-free survival compared to everolimus (16.7 months compared to 14.0 months; one-sided stratified log-rank P = 0.1028; hazard ratio (HR) 0.80 (95% CI 0.56–1.13)), meeting the predefined primary endpoint. Confirmed tumor responses were observed in 31% (95% CI 20%, 41%) of patients receiving combination therapy, as compared to only 12% (95% CI 5%, 19%) of patients receiving treatment with everolimus ( P = 0.0053). Median overall survival duration was similar in the everolimus and combination arm (42.5 and 42.1 months, respectively). Treatment-related toxicities were more common in the combination arm. In summary, treatment with everolimus and bevacizumab led to superior PFS and higher response rates compared to everolimus in patients with advanced pNETs. Although the higher rate of treatment-related adverse events may limit the use of this combination, our results support the continued evaluation of VEGF pathway inhibitors in pNETs.
Evaluation of hearing loss in young adults after exposure to 3.0T MRI with standard hearing protection
Carr, Carrie M. , Lane, John I , Eckel, Larry J, Diehn, Felix E. , Kallmes, Dave F, Carlson, Matthew L. , Shu, Yunhong , Gunderson, Tina M. , Poling, Gayla L. , Carr, Carrie M , Poling, Gayla L , Diehn, Felix E , Lane, John I , Bernstein, Matt A.

Mayo Clinic

The Journal of the Acoustical Society of America | March 21, 2022 | Volume: 151 | Issue: 3 | Pages: 1913-1921

10.1121/10.0009824 | PMID 35364910 Get It

Standard clinical protocols require hearing protection during magnetic resonance imaging (MRI) for patient safety. This investigation prospectively evaluated the auditory function impact of acoustic noise exposure during a 3.0T MRI in healthy adults. Twenty-nine participants with normal hearing underwent a comprehensive audiologic assessment before and immediately following a clinically indicated head MRI. Appropriate hearing protection with earplugs (and pads) was used per standard of practice. To characterize noise hazards, current sound monitoring tools were used to measure levels of pulse sequences measured. A third audiologic test was performed if a significant threshold shift (STS) was identified at the second test, within 30 days post MRI. Some sequences produced high levels (up to 114.5 dBA; 129 dB peak SPL) that required hearing protection but did not exceed 100% daily noise dose. One participant exhibited an STS in the frequency region most highly associated with noise-induced hearing loss. No participants experienced OSHA-defined STS in either ear. Overall, OAE measures did not show evidence of changes in cochlear function after MRI. In conclusion, hearing threshold shifts associated with hearing loss or OAE level shifts reflecting underlying cochlear damage were not detected in any of the 3.0T MRI study participants who used the current recommended hearing protection.
Large-scale Integrated Analysis of Genetics and Metabolomic Data Reveals Potential Links Between Lipids and Colorectal Cancer Risk
Shu, Xiao-Ou , Chen, Zhishan, Long, Jirong, Guo, Xingyi, Yang, Yaohua , Qu, Conghui, Ahn, Yoon-Ok, Cai, Qiuyin , Casey, Graham, Gruber, Stephen B. , Huyghe, Jeroen R. , Jee, Sun Ha, Jenkins, Mark A., Jia, Wei-Hua, Jung, Keum Ji, Kamatani, Yoichiro, Kim, Dong-Hyun, Marchand, Loic Le, Newcomb, Polly A., Oh, Jae Hwan, Ose, Jennifer , Pai, Rish K. , Pan, Zhi-Zhong, Ren, Ze-Fang, Shin, Aesun, Sun, Xiaohui, Tangen, Catherine M., Tanikawa, Chizu, Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Woods, Michael O. , Wu, Anna H., Peters, Ulrike , Jee, Sun Ha , Chen, Zhishan , Shu, Xiao-Ou , Kim, Jeongseon , Kweon, Sun-Seog , Matsuda, Koichi , Matsuo, Keitaro , Ose, Jennifer , Oze, Isao , Pai, R K , Pharoah, Paul D P , Playdon, Mary C , Schoen, Robert E , Shin, Min‐Ho , Shu, Xiao-Ou , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Wolk, Alicja , Woods, Michael O , Peters, Ulrike , Zheng, Wei , Gruber, Stephen B , Cai, Qiuyin , Chen, Zhishan, Long, Jirong, Guo, Xingyi, Yang, Yaohua , Qu, Conghui, Ahn, Yoon-Ok, Casey, Graham, Huyghe, Jeroen R , Jenkins, Mark A., Jia, Wei-Hua, Jung, Keum Ji, Kamatani, Yoichiro, Kim, Dong-Hyun, Marchand, Loic Le, Newcomb, Polly A., Oh, Jae Hwan, Pan, Zhi-Zhong, Ren, Ze-Fang, Shin, Aesun, Sun, Xiaohui, Tangen, Catherine M., Tanikawa, Chizu, Wu, Anna H.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 10, 2022 | Volume: 31 | Issue: 6 | Pages: 1216-1226

10.1158/1055-9965.epi-21-1008 | PMID 35266989 Get It

Abstract Background: The etiology of colorectal cancer is not fully understood. Methods: Using genetic variants and metabolomics data including 217 metabolites from the Framingham Heart Study (n = 1,357), we built genetic prediction models for circulating metabolites. Models with prediction R2 > 0.01 (Nmetabolite = 58) were applied to predict levels of metabolites in two large consortia with a combined sample size of approximately 46,300 cases and 59,200 controls of European and approximately 21,700 cases and 47,400 controls of East Asian (EA) descent. Genetically predicted levels of metabolites were evaluated for their associations with colorectal cancer risk in logistic regressions within each racial group, after which the results were combined by meta-analysis. Results: Of the 58 metabolites tested, 24 metabolites were significantly associated with colorectal cancer risk [Benjamini–Hochberg FDR (BH-FDR) < 0.05] in the European population (ORs ranged from 0.91 to 1.06; P values ranged from 0.02 to 6.4 × 10−8). Twenty one of the 24 associations were replicated in the EA population (ORs ranged from 0.26 to 1.69, BH-FDR < 0.05). In addition, the genetically predicted levels of C16:0 cholesteryl ester was significantly associated with colorectal cancer risk in the EA population only (OREA: 1.94, 95% CI, 1.60−2.36, P = 2.6 × 10−11; OREUR: 1.01, 95% CI, 0.99−1.04, P = 0.3). Nineteen of the 25 metabolites were glycerophospholipids and triacylglycerols (TAG). Eighteen associations exhibited significant heterogeneity between the two racial groups (PEUR-EA-Het < 0.005), which were more strongly associated in the EA population. This integrative study suggested a potential role of lipids, especially certain glycerophospholipids and TAGs, in the etiology of colorectal cancer. Conclusions: This study identified potential novel risk biomarkers for colorectal cancer by integrating genetics and circulating metabolomics data. Impact: The identified metabolites could be developed into new tools for risk assessment of colorectal cancer in both European and EA populations.
Abstract GS4-07: The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts
King, Lorraine , Simpson, Lunden , Khan, Aziz , Harmon, Bryan, Gallagher, Kristalyn K. , Kilgore, Mark , Wei, Shi, King, Tari A. , McAuliffe, Priscilla F. , Nangia, Julie R. , Lee, Joanna , Storniolo, Anna Maria , Thompson, Alastair M. , Burns, Robyn, Veis, Deborah J. , DeSchryver, Katherine, Matusiak, Magdalena , Wang, Jason, Tappenden, Jen, Ding, Daisy Yi , Zhang, Dadong , Jiang, Shu , Straub, Cody, Srivastava, Sucheta, Tibshirani, Rob , Angelo, Robert Michael, Owzar, Kouros , Polyak, Kornelia, Hwang, E. Shelley, Strand, Siri H. , Rivero‐Gutiérrez, Belén , Houlahan, Kathleen E. , Seoane, José Antonio , Risom, Tyler , Vennam, Sujay , Hardman, Timothy, Couch, Fergus J. , DeMichele, Angela , Tseng, Jennifer F. , Gupta, Gaorav P , Zhu, Chunfang , Zhu, Shirley , Luo, Jingqin , Varma, Sushama , Curtis, Christina , Angelo, Robert Michael, Hall, Allison , Polyák, Kornélia , Maley, Carlo C. , Marks, Jeffrey R. , Colditz, Graham A. , West, Robert B.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: GS4-07-GS4-07

10.1158/1538-7445.sabcs21-gs4-07 Get It

Abstract Background. DCIS consists of a molecularly heterogeneous group of premalignant lesions, with variable risk of invasive progression. Understanding biomarkers for invasive progression could help individualize treatment recommendations based upon tumor biology. As part of the NCI Human Tumor Atlas Network (HTAN), we conducted comprehensive genomic analyses on two large DCIS case-control cohorts. Methods. We performed smart3-seq and low-pass whole genome sequencing on two independent, retrospective, longitudinally sampled DCIS case-control cohorts. TBCRC 038 was a multicenter cohort diagnosed with DCIS between 1998 and 2016 at one of the Translational Breast Cancer Research sites; the RAHBT (Resource of Archival Human Breast Tissue) cohort included women identified through the St. Louis Breast Tissue Repository, and the Women’s Health Repository diagnosed between 1997 and 2001. We studied the spectrum of molecular changes present and sought genomic predictors of subsequent ipsilateral breast events (iBEs: DCIS recurrence or invasive progression) in both DCIS epithelium and stroma in formalin fixed paraffin embedded tissue. We generated de novo tumor and stroma-centric subtypes for DCIS that represents fundamental transcriptomic organization. Copy number analysis was performed using low-pass DNA sequencing. Non-negative matrix factorization (NMF) was applied to the RNA expression of all coding genes to identify clusters. A negative-binomial regression model was used to identify differentially expressed genes. Results. We analyzed 677 DCIS samples from 481 patients with 7.1 years median follow-up. In TBCRC samples, we identified three clusters via NMF in TBCRC referred to as ER low, quiescent, and ER high. The ER-low cluster had significantly higher levels of ERBB2 and lower levels of ESR1 compared to quiescent and ER-high clusters. Quiescent cluster lesions were less proliferative and less metabolically active than ER high and ER low subtypes. These findings were replicated in the RAHBT cohort. Focusing on the stromal component of DCIS from laser capture microdissection in RAHBT samples, we identified four distinct DCIS-associated stromal clusters. A “normal-like” stromal cluster with ECM organization and PI3K-AKT signaling; a “collagen-rich” stromal cluster; a “desmoplastic” stromal cluster with high fibroblast and total myeloid abundance, mostly associated with macrophages and myeloid dendritic cells (mDC); and an “immune-dense” stromal cluster. Further, we compared differentially expressed genes in patients with or without subsequent iBEs within 5 years of diagnosis. Hypothesizing that the resulting 812 DE genes (DESeq2) represent multiple routes to subsequent iBEs, we leveraged NMF to identify paths to progression. In both TBCRC and RAHBT cohorts, poor outcome groups exhibited increased ER, MYC signaling, and oxidative phosphorylation, supporting that these pathways are important for DCIS recurrence and progression. Conclusion. Comprehensive genomic profiling in two independent DCIS cohorts with longitudinal outcomes shows distinct DCIS stromal expression patterns and immune cell composition. RNA expression profiles reveal underlying tumor biology that is associated with later iBEs in both cohorts. These studies provide new insight into DCIS biology and will guide the design of diagnostic strategies to prevent invasive progression. Citation Format: Siri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, Jose A Seoane, Lorraine M King, Tyler Risom, Lunden Simpson, Sujay Vennam, Aziz Khan, Timothy Hardman, Bryan E Harmon, Fergus J Couch, Kristalyn Gallagher, Mark Kilgore, Shi Wei, Angela DeMichele, Tari King, Priscilla F McAuliffe, Julie Nangia, Joanna Lee, Jennifer Tseng, Anna Maria Storniolo, Alastair Thompson, Gaorav Gupta, Robyn Burns, Deborah J Veis, Katherine DeSchryver, Chunfang Zhu, Magdalena Matusiak, Jason Wang, Shirley X Zhu, Jen Tappenden, Daisy Yi Ding, Dadong Zhang, Jingqin Luo, Shu Jiang, Sushama Varma, Cody Straub, Sucheta Srivastava, Christina Curtis, Rob Tibshirani, Robert Michael Angelo, Allison Hall, Kouros Owzar, Kornelia Polyak, Carlo Maley, Jeffrey R Marks, Graham A Colditz, E Shelley Hwang, Robert B West. The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS4-07.
Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer
Blarigan, Erin L. Van , Bainter, Tiffany M., Fuchs, Charles S. , Niedzwiecki, Donna , Hantel, Alexander, Benson, Al B. , Atienza, Daniel, Messino, Michael J., Kindler, Hedy L. , Sanoff, Hanna K. , Giovannucci, Edward L. , Ng, Kimmie , Meyerhardt, Jeffrey A. , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Sanoff, Hanna , Ou, Fang‐Shu , Zhang, Sui , Saltz, Leonard B. , Mayer, Robert J. , Venook, Alan P. , Ogino, Shuji

Mayo Clinic

JAMA Network Open | February 22, 2022 | Volume: 5 | Issue: 2 | Pages: e220145

10.1001/jamanetworkopen.2022.0145 | PMID 35191970 Get It

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
Lenz, Heinz‐Josef , Breakstone, Rimini, Crysler, Oxana , Bolch, Emily, Niedzwiecki, Donna , Elsing, Alicia, Hurwitz, Herbert I. , Bekaii‐Saab, Tanios , Zemla, Tyler J, Niedzwiecki, Donna , Bekaii-Saab, Tanios S , Mettu, Niharika B , Ou, Fang‐Shu , Zemla, Tyler , Hálfdánarson, Þorvarður R. , Boland, Patrick M. , Wu, Christina , Nixon, Andrew B. , Fakih, Marwan

Mayo Clinic

JAMA Network Open | February 18, 2022 | Volume: 5 | Issue: 2 | Pages: e2149040

10.1001/jamanetworkopen.2021.49040 | PMID 35179586 Get It

Left–Right Intensity Asymmetries Vary Depending on Scanner Model for FLAIR and T1 Weighted MRI Images
Arani, Arvin , Schwarz, Christopher G. , Wiste, Heather J. , Weigand, Stephen D. , Cogswell, Petrice M. , Murphy, Matthew C. , Trzasko, Joshua D. , Gunter, Jeffrey L. , Senjem, Matthew L. , McGee, Kiaran P. , Shu, Yunhong , Jack, Clifford R. , Initiative, the Alzheimer's Disease Neuroimaging, Bernstein, Matt A , Huston, John , Jack, Clifford R , Schwarz, Christopher G , Arani, Arvin , McGee, Kiaran , Senjem, Matthew L , Cogswell, Petrice M , Gunter, Jeffrey L , Bernstein, Matt A. , Huston, John , Initiative, the Alzheimer's Disease Neuroimaging

Mayo Clinic

Journal of Magnetic Resonance Imaging | February 8, 2022 | Volume: 56 | Issue: 3 | Pages: 917-927

10.1002/jmri.28105 | PMID 35133061 Get It

BackgroundLocalized regions of left–right image intensity asymmetry (LRIA) were incidentally observed on T2‐weighted (T2‐w) and T1‐weighted (T1‐w) diagnostic magnetic resonance imaging (MRI) images. Suspicion of herpes encephalitis resulted in unnecessary follow‐up imaging. A nonbiological imaging artifact that can lead to diagnostic uncertainty was identified.PurposeTo investigate whether systematic LRIA exist for a range of scanner models and to determine if LRIA can introduce diagnostic uncertainty.Study TypeA retrospective study using the Alzheimer's Disease Neuroimaging Initiative (ADNI) data base.SubjectsOne thousand seven hundred fifty‐three (median age: 72, males/females: 878/875) unique participants with longitudinal data were included.Field Strength3T.SequencesT1‐w three‐dimensional inversion‐recovery spoiled gradient‐echo (IR‐SPGR) or magnetization‐prepared rapid gradient‐echo (MP‐RAGE) and T2‐w fluid‐attenuated inversion recovery (FLAIR) long tau fast spin echo inversion recovery (LT‐FSE‐IR). Only General Electric, Philips, and Siemens' product sequences were used.AssessmentLRIA was calculated as the left–right percent difference with respect to the mean intensity from automated anatomical atlas segmented regions. Three neuroradiologists with 37 (**), 32 (**), and 3 (**) years of experience rated the clinical impact of 30 T2‐w three‐dimensional FLAIR exams with LRIA to determine the diagnostic uncertainty. Statistical comparisons between retrospective intensity normalized T1m and original T1‐w images were made.Statistical TestsFor each image type, a linear mixed effects model was fit using LRIA scores from all scanners, regions, and participants as the outcome and age and sex as predictors. Statistical significance was defined as having a P‐value <0.05.ResultsLRIA scores were significantly different from zero on most scanners. All clinicians were uncertain or recommended definite diagnostic follow‐up in 62.5% of cases with LRIA >10%. Individuals with acute brain pathology or focal neurologic deficits are not enrolled in ADNI; therefore, focal signal abnormalities were considered false positives.Data ConclusionLRIA is system specific, systematic, creates diagnostic uncertainty, and impacts IR‐SPGR, MP‐RAGE, and LT‐FSE‐IR product sequences.Level of Evidence: 2Technical Efficacy Stage: 3
REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinot
Ahn, Daniel H. , Sonbol, Bassam Bassam, Wender, Donald B., Klute, Kelsey , Waechter, Blake, Lenz, Heinz‐Josef , Ou, Fang‐Shu , Jin, Zhaohui , Jones, Jeremy C , Ulrich, Angela, Young, Heather, Weinberg, Benjamin A. , Strickler, John H. , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: TPS213-TPS213

10.1200/jco.2022.40.4_suppl.tps213 Get It

TPS213 Background: Regorafenib (R) is an oral multikinase inhibitor that blocks several protein kinases involved in angiogenesis and oncogenesis; it has a survival benefit in refractory metastatic colorectal cancer (mCRC). The current standard (std) treatment in patients (pts) with RAS wildtype (WT) mCRC is sequential treatment with an anti-EGFR antibody (AEA) followed by R. However, R, which is orally administered once daily, may be more convenient and thus preferable for pts than AEA. REVERCE, a Japanese trial, demonstrated a significant 5.8 month (mo.) survival benefit with regorafenib administered prior to AEA compared to the std sequence. Based off these findings, the proposed phase II trial is to confirm the observed survival benefit from regorafenib sequencing prior to anti-EGFR monoclonal antibody therapy in REVERCE in a US patient population. Methods: REVERCEII is an Academic and Community Cancer Research United (ACCRU) network-led randomized phase II study of R (dose escalation from 80mg to 160mg based on tolerance) prior to AEA (R+AEA) compared to standard sequencing (AEA+R) in pts with refractory RAS WT mCRC. Patients are randomized 1:1 to receive R (Arm A) vs. AEA (with or without irinotecan per investigator choice) (Arm B). At the time of disease progression or intolerance, patients will receive sequential treatment until disease progression. Eligibility criteria include histologically confirmed mCRC, ECOG ≤ 2, acceptable organ function, and patients must have had prior fluoropyrimidine, oxaliplatin and irinotecan, and no prior AEA nor R. The primary objective is to compare the overall survival (OS), the primary endpoint, between evaluable patients (eligible, consented, started protocol treatment) who were randomized to R+AEA (arm A) and AEA+R (arm B). With 83 OS events, we have 87% power to detect an improvement in median OS from 9 months to 14.5 mo., assuming 1-sided significance level of 0.15, and exponential distribution. The total sample size is 124 patients. Secondary endpoints include progression-free survival, objective response, and adverse events. The total study duration is expected to be 3 years. Clinical trial information: NCT04117945. Clinical trial information: 04117945.
A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.
Walden, Daniel , Shaib, Walid L. , Ahn, Daniel H. , El‐Rayes, Bassel F. , Hobday, Timothy J. , Bruggeman, Sarah, Jaszewski, Brandy L., El-Rayes, Bassel F , Wee, Wen , Zemla, Tyler , McWilliams, Robert R. , Hálfdánarson, Þorvarður R. , Ou, Fang‐Shu , Wu, Christina , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 563-563

10.1200/jco.2022.40.4_suppl.563 Get It

563 Background: RUB is an oral PARP1,2,3 inhibitor that demonstrated efficacy in patients (pts) with ovarian and prostate cancers harboring deleterious BRCA mutations. RUB exerts synergistic anti-tumor effect with IRI preclinically though the combination has overlapping toxicities. We previously published on the population PK of nal-IRI (Adiwijaya, Ma et al, Clin Pharm Ther 2017). We conducted a phase I study to evaluate a novel sequential dosing of RUB with nal-IRI/5FU in mGI cancer pts. Methods: Eligible pts had incurable mGI cancer previously received > 1 line of therapy (rx), ECOG PS 0-1, had RECIST measurable disease, adequate organ reserves and not received IRI for metastatic disease. Previous PARPi rx was excluded. The endpoints included dose limiting toxicity (DLT), maximum tolerated dose (MTD) and toxicity profile. The dose escalation utilized the 3+3 design. RUB was given oral bid on Day 4 to 13 and 18 to 27 with nal-IRI i.v. and 5FU i.v. 2400 mg/m2 over 46 hr on Day 1 and 15, every 28 day. Planned dose levels were RUB 400 mg/nal-IRI 50 mg/m2 (DL1), 400 mg/70 mg/m2 (DL2) and 600 mg/70 mg/m2 (DL3). Adverse events (AEs) were scored per CTCAE v4.03. Molecular profile was evaluated by CLIA-certified NGS testing. Results: Eighteen pts including 11 colorectal (CRC), 6 PANC, 1 gastroesophageal (GE) were enrolled and 12 were evaluable for DLTs. DL2 was not tolerable (DLT: G3 diarrhea, nausea and vomiting) and DL2A was added (RUB 600 mg/nal-IRI 50 mg/m2). DL2A enrolled 6 pts with no DLT and was determined as the MTD. Of DLT-evaluable pts, G3 and worse treatment-related AEs from all cycles were diarrhea (33%), fatigue (25%), leukopenia (25%), neutropenia (25%), anemia (8%) and nausea (8%). Four of 12 response evaluable pts had partial response: 2 CRC (1 had ATM mut), 1 PANC ( ATM mut), 1 GE ( BRCA2 mut) whilst 3 responders previously had platinum (PLA). Five pts had stable disease beyond 16 weeks (range 18.9 to 100.7 weeks), and all had prior PLA. Conclusions: The study successfully determined the MTD of RUB in combination with nal-IRI and 5FU. Encouraging efficacy was observed in PLA-treated mGI cancers including responses in those harboring ATM and BRCA alterations. The study is proceeding to evaluate the efficacy of the combination in metastatic pancreas cancer pts with and without BRCA1/2 or PALB2 alterations. Clinical trial information: NCT03337087.
Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial.
Innocenti, Federico , Lenz, Heinz‐Josef , Raghav, Kanwal , Ou, Fang‐Shu , Venook, Alan P. , Sun, Ryan , Kopetz, Scott

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 193-193

10.1200/jco.2022.40.4_suppl.193 Get It

193 Background: Enhanced understanding of the evolving clonal architecture under treatment stress is crucial to optimizing care and developing effective therapies in metastatic colorectal cancer (mCRC). Emergence of genomic alterations (GAs) [mutations (muts) and amplifications (amps)] in RAS, BRAF, EGFR, ERBB2, and MET have been recognized as key resistance mechanisms to anti-EGFR therapy in later lines in mCRC. Data regarding occurrence of these GAs under selective pressure in the first line setting is lacking. Methods: CALGB/SWOG 80405 was a randomized trial of bevacizumab (bev) vs cetuximab (cet) in first line mCRC. Patients (pts) with paired plasma samples (pre-treatment and post-progression) available for circulating tumor DNA (ctDNA) testing were included in this substudy. Sequencing of ctDNA was performed by Guardant360 assay in a CLIA-certified environment to detect GAs in 73 genes. RAS/BRAF status [mut vs. wild type (wt)] was based on clonal muts [pre-defined cutoff of relative MAF (rMAF) ≥ 25%] in ctDNA. Only samples with ≥1 GA were analyzed to minimize false negatives. The primary objective was to determine and compare prevalence of acquired GAs between study arms: bev (anti-VEGF) and cet (anti-EGFR). Descriptive statistics and Fisher’s exact test were used. Results: Baseline characteristics of ctDNA cohort were similar to the 80405 population. Among 133 randomized RAS/BRAF wt pts, 11 (15.3%) and 5 (8.2%) developed acquired GAs (OR 2.0, P = 0.29), in bev and cet arm, respectively. Key comparative data for pts with regard to acquired pathogenic GAs are shown in the table. Conclusions: In this randomized mCRC cohort, the ctDNA profile of acquired GAs with front line anti-EGFR chemotherapy appears to be strikingly distinct from that seen with later lines of therapy. Acquisition of GAs, classically associated with EGFR resistance in later line, was not only rare with upfront cet-chemotherapy but also comparable to bev-containing (anti-VEGF) regimen. The mechanisms of acquired resistance appear to differ when anti-EGFR therapy is administered in combination with highly active first line chemotherapy. Our findings have critical translational relevance to the timing and value of ctDNA-guided anti-EGFR rechallenge in mCRC pts, especially in those treated with anti-EGFR therapy upfront.[Table: see text]